Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or pharmacological treatment?
https://doi.org/10.15829/1728-8800-2021-2888
Abstract
This review describes the results of randomized, controlled clinical trials comparing the outcomes of stable coronary artery disease after myocardial revascularization and non-invasive treatment, including the recently published results of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). New potentials for improving the prognosis in stable coronary artery disease with the help of drug treatment are characterized, the role of which has not yet been evaluated in studies comparing the effectiveness of invasive and conservative approaches to the management of such patients.
Keywords
coronary artery disease,
myocardial revascularization,
drug therapy,
percutaneous coronary intervention,
coronary artery bypass grafting,
prevention,
atherosclerosis
Supporting agencies: The publication was prepared with the support of Bayer JSC. Approval number: PP-XAR-RU-0748-1.
About the Author
I. S. Yavelov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow.
References
1. Boden WE, O'Rourke RA, Teo KK, et al., for the COURAGE Trial Research Group. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med. 2007;356:1503-16. doi:10.1056/NEJMoa070829.
2. Sedlis SP, Hartigan PM, Teo KK, et al., for the COURAGE Trial Investigators. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med. 2015;373:1937-46. doi:10.1056/NEJMoa1505532.
3. Shaw LJ, Berman DaS, Maron DJ, et al., for the COURAGE Investigators. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy. Circulation. 2008;117(10):1283-91. doi:10.1161/CIRCULATIONAHA.107.743963
4. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography. Circulation. 2003;107:2900-6. doi:10.1161/01.CIR.0000072790.23090.41.
5. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859. doi:10.1136/bmj.g3859.
6. Xaplanteris P, Fournier S, Pijls NHJ, et al; FAME 2 Investigators. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379(3):250-259. doi:10.1056/NEJMoa1803538.
7. De Bruyne B, Fearon WF, Pijls NHJ, et al., for the FAME 2 Trial Investigators. Fractional Flow Reserve — Guided PCI for Stable Coronary Artery Disease. N Engl J Med. 2014;371:1208-17. doi:10.1056/NEJMoa1408758
8. Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019;40(2):180-186. doi:10.1093/eurheartj/ehy812.
9. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165. doi:10.1093/eurheartj/ehy394.
10. Knuuti J, Wijns W, Saraste A, et al. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-77. doi:10.1093/eurheartj/ehz425.
11. Maron DJ, Hochman JS, Reynolds HR, et al., for the ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395-407. doi:10.1056/NEJMoa1915922.
12. Lopes RD, Alexander KP, Stevens SR, et al. Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial. Circulation. 2020;142:1725-35. doi:10.1161/CIRCULATIONAHA.120.050304.
13. Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019;ehz430. doi:10.1093/eurheartj/ehz430.
14. Nidorf SM, Fiolet ATL, Mosterd A, et al, for the LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383:1838-47. doi:10.1056/NEJMoa2021372.
15. Ridker PM, Everett BM, Thuren T, et al., for the CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-31. doi:10.1056/NEJMoa1707914.
16. Tong DC, Quinn S, Nasis A, et al. Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890-1900. doi:10.1161/CIRCULATIONAHA.120.050771.
17. Eikelboom JW, Connolly SJ, Bosch J, et al., for the COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. doi:10.1056/NEJMoa1709118.
18. Connolly SJ, Eikelboom JW, Bosch J, et al., on behalf of the COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2017;391(10117):205-18. doi:10.1016/S0140-6736(17)32458-3.
19. Steffel J, Eikelboom JW, Anand SS, et al. The COMPASS Trial. Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020;142:40-8. doi:10.1161/CIRCULATIONAHA.120.046048.
20. Bainey KR, Welsh RC, Connolly SJ, on behalf of the COMPASS investigators. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 2020;141:1141-51. doi:10.1161/CIRCULATIONAHA.119.044598.
21. Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. The COMPASS-CABG Study. JACC. 2019;73:121-30. doi:10.1016/j.jacc.2018.10.048.
22. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.)
Review
For citations:
Yavelov I.S. Prevention of cardiovascular events in patients with stable coronary artery disease: myocardial revascularization or pharmacological treatment? Cardiovascular Therapy and Prevention. 2021;20(3):2888. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2888
Views:
850
Email this article 
